Days after departing from Omnicom Health Group (OHG), Matt McNally has returned to Publicis Groupe to serve as global CEO of ...

Royalty Pharma ( ($RPRX) ) has provided an announcement. Royalty Pharma announced its acquisition of RP Management, LLC, aiming to simplify its ...

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

At issue is the role pharmacy benefit mangers play in taking large discounts on drugs that advocates say are not passed along ...

The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is ...

Before transitioning from music to health care, as a student, I learned about the works of composers such as Igor Stravinsky, ...

Executive interviews feature innovators and visionaries explaining the critical role that digital technologies play in ...

Incremental Opportunities: The industry is set to create an incremental opportunity of USD 20.1 billion, rising 1.7 times its ...

This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...

Matt McNally is rejoining Publicis. The ad exec has taken the global CEO post at Publicis Health, returning to a company ...

Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with ...

The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future ...